Please login to the form below

“Regulatory barriers to patient care; HCP perspectives on Medical Education

Ashfield Meetings & Events’ Andrew Moore and Lee-Anne Penn presented findings of new white paper – The Science Of Healthcare Professional Meetings at IPCAA

Ashfield Meetings & Events, part of UDG Healthcare, presented the findings of its latest white paper The Science Of Healthcare Professional Meetings at this year’s IPCAA Annual Seminar on Compliance in Berlin on 20th and 21st March. 

As a follow on from the international healthcare events specialist’s 2016 study – The Future of Meetings – Andrew Moore, Ashfield’s Head of Technology & Compliance, and Client Relationship Director, Lee-Anne Penn compared and contrasted the perceptions of healthcare professionals (HCPs) across a wide variety of speciality areas, diving deeper into the ongoing evolution of the medical meetings landscape.

“In this, our latest study, we’ve looked at the individual component factors of why HCPs attend events to better understand their motivations and desires,” Andrew Moore explained to the audience of professionals working in healthcare meetings, including those from industry, associations, regulatory bodies, PCIs and event agencies. “This has helped us really define a strategy for successful meetings in the future.”

Andrew Moore highlighted, “It was encouraging to discover that HCPs are saying their ‘preferred channel’ for receiving scientific content is through attendance at a scientific congress or meeting, but it was also important to explore any barriers they felt might be impacting their ability to attend – including regulatory barriers.”

Andrew and Lee-Anne also spoke about the white paper’s conclusions around the impact of Transfer of Value disclosure, the importance of a return on the time and money invested in attending, and the value and effect real-life experiences from patients have in HCPs’ learning.

“It is clear that there are a number of barriers to HCP’s attending scientific congresses and meetings. Increasingly a consumer driven mindset is being adopted by HCPs, who are more closely assessing which meetings to attend. It is crucial to place the needs of the HCP at the centre of the planning process.”

“Collating the data for the Science Of Meetings has been invaluable,” concluded Lee-Anne Penn at the well-attended event. “Its findings will not only help healthcare companies deliver insight-led, personalised HCP experiences that guarantee both engagement and impact, but it will also reassure HCPs that they are being listened to as events evolve to meet their needs.”

5th April 2018



Company Details


Contact Website

Ashfield House
Resolution Road
Ashby de la Zouch
LE65 1HW

Latest content on this profile

Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
Ashfield Meetings & Events, the largest full service event management agency specialising in serving the healthcare sector, has this month welcomed its largest intake of students to its highly successful university placement scheme.
‘Delivering healthcare events with certainty and impact’
Ashfield Meetings & Events launches new website
The Ashfield Solution - Accelerate product uptake and maximize ROI
A pioneering multichannel optimization model powered by advanced analytics with the ability to flex resources based on real time results.
Patient Engagement and Experience Conference, 16-17 May
Ashfield and S3 Connected Health, Silver Sponsors at the 3rd Annual Patient Engagement and Experience Conference in Amsterdam on 16-17 May, will be speaking on how digitally enhanced Patient Support Programmes can extend the continuity and relevance of care into patients’ everyday lives.
Ashfield will be exhibiting at ISMPP US
On 30 April - 2 May 2018, Ashfield Healthcare Communications will be exhibiting at the 14th Annual Meeting of ISMPP at the Gaylord National Resort & Convention Center, National Harbor, MD.
Putting the patient first
You’ve invested millions in the development of your new drug or therapy and have successfully completed clinical trials - now you are ready to launch. Data has been collected, efficacy is understood and side effects are recorded. But an important question remains: is your target patient population prepared?